Serrao Gregory, Vinayak Manish, Nicolas Johny, Subramaniam Varsha, Lai Ashton C, Laskey Daniel, Kini Annapoorna, Seethamraju Harish, Scheinin Scott
Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA.
J Clin Med. 2023 Dec 13;12(24):7644. doi: 10.3390/jcm12247644.
Lung transplantation can greatly improve quality of life and extend survival in those with end-stage lung disease. In order to derive the maximal benefit from such a procedure, patients must be carefully selected and be otherwise healthy enough to survive a high-risk surgery and sometimes prolonged immunosuppressive therapy following surgery. Patients therefore must be critically assessed prior to being listed for transplantation with close attention paid towards assessment of cardiovascular health and operative risk. One of the biggest dictators of this is coronary artery disease. In this review article, we discuss the assessment and management of coronary artery disease in the potential lung transplant candidate.
肺移植可以极大地改善终末期肺病患者的生活质量并延长其生存期。为了从这一手术中获得最大益处,必须仔细挑选患者,且患者在其他方面要足够健康,以承受高风险手术以及有时术后长时间的免疫抑制治疗。因此,在将患者列入移植名单之前,必须对其进行严格评估,同时要密切关注心血管健康评估和手术风险。其中最大的决定因素之一就是冠状动脉疾病。在这篇综述文章中,我们讨论了潜在肺移植受者冠状动脉疾病的评估与管理。